Loibl S, Majewski I, Guarneri V, Nekljudova V, et al. Corrections to "PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab". Ann Oncol 2019;30:1180.
PMID: 31987390